Research has been conducted on the long-term cardiovascular outcomes of patients who have experienced myocarditis related to immune checkpoint inhibitor therapy. The studies have investigated various aspects, including diagnostic and prognostic values, cardiotoxicity, and potential treatment options. The findings appear to provide insights into the risks and management of cardiovascular adverse effects associated with immune checkpoint inhibitors.